Oncotelic's Innovative Pipeline Poised for Market Growth Under Expert Leadership

Oncotelic Therapeutics (OTCQB: OTLC) is prominently featured in a new NetworkNewsAudio Audio Press Release that highlights the company's innovative therapeutics pipeline and its potential for strong market growth. The release emphasizes the exceptional leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy, and nanomedicine. Dr. Trieu's impressive track record includes developing Abraxane®, a nanotechnology-based formulation that revolutionized treatment for breast, lung, and pancreatic cancers, and advancing Cynviloq™, a novel micellar paclitaxel therapy. His expertise positions Oncotelic to advance pioneering therapies with substantial market potential.

As a clinical-stage biopharmaceutical company, Oncotelic Therapeutics focuses on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. The company benefits from Dr. Trieu's robust portfolio of inventions, which includes over 150 patent applications and 39 issued U.S. patents. Beyond its internal drug pipeline, Oncotelic strategically licenses and co-develops select drug candidates through joint ventures, notably holding a 45% stake in GMP Bio. This joint venture, under Trieu's leadership, advances its own pipeline of drug candidates that complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics, making it a key player in the biopharmaceutical landscape.